Table 1. Comparison of baseline characteristics among patients with common and uncommon EGFR mutations.
| Characteristics | 19del/21L858R (n=32), n (%) | G719X/L861Q/S768I/complex (n=19), n (%) | 20ins (n=7), n (%) | P value |
|---|---|---|---|---|
| Age (years) | 0.601 | |||
| <65 | 20 (62.5) | 12 (63.2) | 3 (42.9) | |
| ≥65 | 12 (37.5) | 7 (36.8) | 4 (57.1) | |
| Sex | 0.446 | |||
| Male | 15 (46.9) | 11 (57.9) | 5 (71.4) | |
| Female | 17 (53.1) | 8 (42.1) | 2 (28.6) | |
| Smoking history | 0.451 | |||
| No | 20 (62.5) | 9 (47.4) | 3 (42.9) | |
| Ever/current | 12 (27.5) | 10 (52.6) | 4 (57.1) | |
| Stage | 0.155 | |||
| IIIB/IIIC | 2 (6.3) | 4 (21.1) | 0 (0.0) | |
| IV | 30 (93.8) | 15 (78.9) | 7 (100.0) | |
| Treatment line | 0.852 | |||
| First-line | 15 (46.9) | 10 (52.6) | 4 (57.1) | |
| ≥ Second-line | 17 (53.1) | 9 (47.4) | 3 (42.9) | |
| Brain metastasis | 0.376 | |||
| No | 28 (87.5) | 14 (73.7) | 5 (71.4) | |
| Yes | 4 (12.5) | 5 (26.3) | 2 (28.6) | |
| Number of metastatic sites | 0.702 | |||
| <3 | 27 (84.4) | 15 (78.9) | 5 (71.4) | |
| ≥3 | 5 (15.6) | 4 (21.1) | 2 (28.6) |
EGFR, epidermal growth factor receptor; 19del, exon 19 deletions; 21L858R, exon 21 L858R; 20ins, exon 20 insertions.